Shi Tingting, Qu Guangbo, Zhang Yun, Hou Lijuan, Jin Yuhui
Department of Immunization Program, Hefei Center for Disease Control and Prevention, Hefei, Anhui, China.
Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
Hum Vaccin Immunother. 2025 Dec;21(1):2511359. doi: 10.1080/21645515.2025.2511359. Epub 2025 Jun 5.
To quantitatively assess the incremental protective effect of two-dose mumps vaccination in Hefei. Monthly mumps incidence during 2011-2023 were collected. The Interrupted Time Series and Segmented Regression Analyses (ITSA) were employed to evaluate the variations in monthly mumps incidence following the introduction of one-dose mumps-containing vaccine (MuCV) and two-dose measles-mumps-rubella combined attenuated live vaccine (MMR) into the Expanded Program on Immunization (EPI). The average annual incidence was 16.95 per 100,000 population (18.75 and 10.95 in one-dose and two-dose vaccination periods respectively). The incidence was the highest among children aged 5-14. ITSA revealed that monthly incidences of mumps decreased by 0.015 per 100,000 (β = -0.015, < .001) in one-dose MuCV vaccination period. The incidence decreased in all four age groups, with the largest decline observed among children aged 10-14 (β = -0.139, < .001), followed by children aged 5-9 (β = -0.089, = .003). In two-dose MMR vaccination period, the monthly incidence of total population, 0-4, 5-9, 10-14 and ≥15 average decreased by 0.014, 0.109, 0.133, 0.018, and 0.0003 (β+β) per 100,000, respectively. The mumps incidence decreased over time with the highest annual incidence shifting to young children. One-dose MuCV vaccination significantly reduced the incidence of mumps, with the largest decline observed among children aged 5-14, but the effect diminishes in older age groups. Booster vaccination for adolescents over 10 years old or optimizing the dose interval might be a good option to effectively control the incidence of mumps. The impact of the two-dose MMR immunization strategy on the trend of mumps morbidity necessitates additional investigation.
为定量评估合肥两剂次腮腺炎疫苗接种的增量保护效果。收集了2011 - 2023年期间的腮腺炎月发病率。采用中断时间序列和分段回归分析（ITSA）来评估在扩大免疫规划（EPI）中引入一剂次含腮腺炎疫苗（MuCV）和两剂次麻疹 - 腮腺炎 - 风疹联合减毒活疫苗（MMR）后腮腺炎月发病率的变化。平均年发病率为每10万人16.95例（一剂次和两剂次接种期间分别为18.75例和10.95例）。发病率在5 - 14岁儿童中最高。ITSA显示，在一剂次MuCV接种期间，腮腺炎月发病率每10万人下降0.015例（β = -0.015，P <.001）。所有四个年龄组的发病率均下降，其中10 - 14岁儿童下降幅度最大（β = -0.139，P <.001），其次是5 - 9岁儿童（β = -0.089，P =.003）。在两剂次MMR接种期间，总人口、0 - 4岁、5 - 9岁、10 - 14岁和≥15岁人群的腮腺炎月发病率每10万人分别平均下降0.014、0.109、0.133、0.018和0.0003例（β + β）。腮腺炎发病率随时间下降，年发病率最高值转移到幼儿。一剂次MuCV接种显著降低了腮腺炎发病率，5 - 14岁儿童下降幅度最大，但在年龄较大的年龄组中效果减弱。对10岁以上青少年进行加强免疫或优化剂次间隔可能是有效控制腮腺炎发病率的一个好选择。两剂次MMR免疫策略对腮腺炎发病趋势的影响需要进一步研究。
